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Background: MicroRNA (miRNA)-related single nucleotide polymorphisms (SNPs) may compromise miRNA binding
affinity and modify mRNA expression levels of the target genes, thus leading to cancer susceptibility. However, few
studies have investigated roles of miRNA-related SNPs in the etiology of cervical carcinoma.
Methods: In this case–control study of 1,584 cervical cancer cases and 1,394 cancer-free female controls, we
investigated associations between two miR-218-related SNPs involved in the LAMB3-miR-218 pathway and the risk of
cervical carcinoma in Eastern Chinese women.
Results: We found that the pri-miR-218 rs11134527 variant GG genotype was significantly associated with a
decreased risk of cervical carcinoma compared with AA/AG genotypes (adjusted OR=0.77, 95% CI=0.63-0.95,
P=0.015). However, this association was not observed for the miR-218 binding site SNP (rs2566) on LAMB3. Using
the multifactor dimensionality reduction analysis, we observed some evidence of interactions of these two SNPs
with other risk factors, especially age at primiparity and menopausal status, in the risk of cervical carcinoma.
Conclusions: The pri-miR-218 rs11134527 SNP was significantly associated with the risk of cervical carcinoma in
Eastern Chinese women. Larger, independent studies are warranted to validate our findings.
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MicroRNAs (miRNAs) are single-stranded 21–23 nu-
cleotide (nt) long endogenous noncoding RNAs that
regulate the mRNA expression of numerous target genes
[1]. Disregulation of these target genes could alter bio-
logical processes as a result of either degradation of tar-
get mRNAs or repression of their translation by miRNA
binding to their 30-untranslated regions (UTRs) [2].
Accumulated data have shown that the deregulation of
miRNAs is involved in cell differentiation, proliferation,
apoptosis and carcinogenesis [3]. MiRNAs include pri-
mary (pri-), precursor (pre-) and mature miRNA, in
which single nucleotide polymorphisms (SNPs) of these
miRNAs or in their binding sites on their target genes
may compromise miRNA binding affinity and change
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reproduction in any medium, provided the orto cancer susceptibility [4,5]. Several recent studies have
indicated that miRNA-related SNPs, especially those
located at miRNA binding sites or miRNAs themselves,
can remarkably alter the biogenesis and/or function of
the corresponding miRNAs and thus the risk of human
cancers [4,6].
Cervical carcinoma is the third most commonly
diagnosed cancer and the fourth leading cause of cancer
deaths in women worldwide, accounting for 9%
(529,800) of the new cancer cases and 8% (275,100) of
the cancer deaths among women in 2008 [7]. More than
85% of these cases and deaths occur in developing coun-
tries, including China [7]. Invasive cervical cancer can
be divided into two major histological types of squamous
cell carcinoma (SCC) and adenocarcinoma, and SCC
accounts for about 85% of the cases [8,9]. A large body
of research in molecular epidemiology supports the hy-
pothesis that persistent infection with oncogenic human
papillomavirus (HPV), especially high-risk HPV types, is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Shi et al. BMC Cancer 2013, 13:19 Page 2 of 8
http://www.biomedcentral.com/1471-2407/13/19the primary cause of cervical carcinoma, deemed as a
necessary cause for the disease [7,10].
Recent studies have found that the expression levels of
miR-218 were associated with infection of high-risk
HPV involved in the pathogenesis of cervical cancer
[11]. Specifically, in high-risk HPV16-positive cell lines,
the upregulation of E6 oncoprotein could reduce the
miR-218 expression; in contrast, the RNA interference
of E6 oncogene increased the miR-218 expression [12].
Moreover, the Laminin 5 β3 (LAMB3) gene has been
found to be one of transcriptional targets of miR-218
[12]. LAMB3 was expressed in many epithelial tissues
and was involved in tumor microenvironment by in-
creasing carcinoma cell migration [13]. Others reported
that LAMB3 might upregulate the expression levels of
the HPV16 E6 oncoprotein though miR-218 [12]. There-
fore, the LAMB3-miR-218 pathway may be involved in
the process of high-risk HPV infection and thus contrib-
ute to cervical carcinogenesis. However, its intrinsic
mechanisms are still unclear. It is likely that miRNAs
and related genetic variations may have effects on cancer
development [6]. To date, only two reported studies
have investigated the associations between three
miRNA-related SNPs and the risk of cervical carcinoma
[6,14], two of which (i.e., pri-miR-218 rs11134527 and
LAMB3 rs2566) are found to be associated with altered
risk of cervical cancer in a Chinese Han population [6].
To further test the hypothesis that miRNA-related SNPs
involved in the LAMB3-miR-218 pathway contribute to
cervical cancer risk, we performed a case–control study
with a much larger sample size to validate the reported




The study population consisted of 1,584 cervical carcin-
oma patients, who had been operated between February
2008 and March 2011 in Fudan University Shanghai
Cancer Center (FUSCC). The tumors were histopatho-
logically confirmed independently as primary cervical
carcinoma by two gynecologic pathologists as routine
diagnosis at FUSCC. An additional 1,394 cancer-free fe-
male controls were enrolled from women who had come
to the Outpatient Department of Breast Surgery at
FUSCC for breast cancer screening and agreed to par-
ticipate in this study. These female controls, with the
selection criteria including no individual history of
cancer, were genetically unrelated and frequency
matched to the cases on age (± 5 years) and residen-
tial areas in Eastern China.
During an in-person survey, all potential subjects were
interviewed to identify their willingness to participate in
this study. As a result, a response rate for the cases andcontrols was of approximate 95% and 95%, respectively.
Because the vast majority of Chinese women are non-
smokers and non-drinkers, our study populations were
restricted to women who did not smoke cigarettes or
drink alcohol. For the cases, detailed clinico-pathologic
information was extracted from the patients0 electronic
database of FUSCC, including tumor histology [15],
FIGO stage (International Federation of Gynecology and
Obstetrics, 2009), tumor size (i.e., the size of the primary
tumor was the largest tumor diameter), pelvic lymph
node (LN) metastasis, lympho-vascular space invasion
(LVSI), depth of cervical stromal invasion and the ex-
pression of estrogen receptor (ER) and progesterone re-
ceptor (PR). Each participant provided a one-time 10 ml
of venous blood sample (after the diagnosis and before
the initiation of treatment for the cases), and samples
were kept frozen till DNA extraction for genotyping. All
samples were obtained from tissue bank of FUSCC. The
research was approved by the Institutional Review Board
of FUSCC, and a written informed consent was obtained
from all recruited individuals. Each clinical investigation
was conducted according to the principles expressed in
the Declaration of Helsinki consent.
SNP selection and genotyping
The SNPs were selected from the NCBI dbSNP data-
base (http://www.ncbi.nlm.nih.gov/projects/SNP) and the
International HapMap Project database (http://hapmap.
ncbi.nlm.nih.gov/) based on four criteria: 1) located at
the pri-miR-218 gene region or 30-UTR of the LAMB3
gene, 2) minor allele frequency (MAF) ≥ 5% in Chinese
Han populations, 3) with low linkage disequilibrium by
using an r2 threshold of < 0.8 for each other, and 4) pre-
dicted as potentially functional SNPs by SNP function
prediction (FuncPred) software from National Institute
of Environmental Health Sciences (http://snpinfo.niehs.nih.
gov/snpfunc.htm). As a result, only two reported SNPs (i.e.,
pri-miR-218 rs11134527 and LAMB3 rs2566) were selected,
because pri-miR-218 rs11134527 was predicted to be func-
tional and LAMB3 rs2566 was the only one SNP residing
in the miR-218 binding site. Genomic DNA was obtained
from the whole blood, and the Taqman assay was per-
formed for genotyping, as described previously [16,17].
Four negative controls (without DNA template), duplicated
positive controls and eight repeat samples were included in
each 384-fomate for the quality control. As a result, the
mean genotyping rate was 99.3%, and the discrepancy rate
in all positive controls (i.e., duplicated samples, overlapping
samples from previous studies and samples randomly
selected to be sequenced) was less than 0.1%.
Multifactor dimensionality reduction (MDR) analysis
To further explore high-order gene-environment inter-
actions that were individually involved in cervical cancer
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viously [17,18]. This approach was used to find the main
factor and the combination of multiple factors (in this
case, SNPs and environmental risk factors) that were
significantly associated with cancer risk. As a result,
the model that minimized the prediction error and
maximized the cross-validation consistency (CVC) was
chosen. To reduce the probability of bias, we used differ-
ent random seeds to repeat the complete analysis for 10
times, and permutated the status of cases and controls
in the data set then repeated the test 1000 times under
the null hypothesis of no association. This analysis was
performed by using the MDR V2.0 beta 8.2 program
(http://www.multifactordimensionalityreduction.org/).
Statistical analysis
The differences in selected variables between cervical
carcinoma cases and female controls were evaluated by
the Pearson's χ2-test. The associations of genotypes with
the risk of cervical carcinoma were estimated by com-
puting odds ratios (ORs) and their 95% confidence inter-
vals (CIs) from both univariate and multivariate logistic
regression models, with or without adjustment for age,
age at primiparity, menopausal status and body mass
index (BMI) [19]. The associations of SNP genotypes
with cervical carcinoma risk were also stratified by
demographic and clinico-pathologic variables. We also
performed homogeneity test and logistic regression ana-
lysis to estimate and compare the risks between the
strata and interactions between two factors, respectively.
For all significant genetic effects observed in our study,
we calculated the false-positive report probability (FPRP)
with prior probabilities of 0.0001, 0.001, 0.01, 0.1 and
0.25 to test for false-positive associations [20]. A FPRP
value < 0.2 was considered a noteworthy and indicated a
remained robust association for a given prior probability.
Statistical power was estimated to detect an OR of 1.50/
0.67 (for a risk/protective effect), with an α level equal
to the observed P value [20]. All statistical analyses were
performed with SAS software (version 9.1; SAS Institute,
Cary, NC), unless stated otherwise. All P values were
two-sided with a significance level of P < 0.05.
Results
Among all studied subjects, 19 cases and three controls
failed to be genotyped after repeated assays. Thus, the
final analysis included 1,565 cases and 1,391 controls. As
showed in Additional file 1: Table S1, there were no sig-
nificant differences in the distributions of age between
the cases and the controls with similar mean ages
of 45.8 (± 9.8) and 46.1 (± 8.9) years, respectively
(P=0.226). The cases were more likely to be premeno-
pausal (72.5% vs. 60.5%), thinner (BMI < 25 kg/m2,
78.2% vs. 65.9%) and younger at primiparity (≤ 24 yr,63.2% vs. 51.0%) than the controls. Because the differ-
ences in age at primiparity, menopausal status and
BMI were significant between cases and controls (all
P<0.001), these variables were further adjusted for any
residual confounding effect in later multivariate logistic
regression analyses.
The genotype frequencies of the pri-miR-218 rs11134527
and LAMB3 rs2566 SNPs as well as their associations with
the risk of cervical carcinoma are summarized in Table 1.
All observed genotype distributions in the 1,391 controls
agreed with the Hardy-Weinberg equilibrium (HWE,
P=0.083 and 0.094 for rs11134527 and rs2566, respectively).
In the recessive genetic model, the pri-miR-218 rs11134527
variant GG genotype was significantly associated with a
decreased risk of cervical carcinoma compared with the
AA and AA/AG genotypes (adjusted OR=0.79 and 0.77,
95% CI=0.63-0.99 and 0.63-0.95, P=0.039 and 0.015, re-
spectively). However, this association was not observed for
the LAMB3 rs2566 SNP.
In stratification analyses, as showed in Table 2, under
a recessive genetic model, a decreased cervical carcin-
oma risk associated with the pri-miR-218 rs11134527
GG genotype was more evident in women who were
younger at primiparity (≤ 24 yr, adjusted OR=0.73, 95%
CI=0.56-0.96, P=0.022) or premenopausal (adjusted
OR=0.73, 95% CI=0.57-0.94, P=0.013), which was also
observed for subgroups of SCC, FIGO stage I, stage II,
positive pelvic LN, positive LVSI, deep cervical stromal
invasion (> 1/2) and negative expression of ER and PR
(P=0.008, 0.008, 0.028, 0.002, 0.008, 0.022, 0.011 and
0.014, respectively). However, homogeneity tests sug-
gested that there was no difference in risk estimates
between the strata (Table 2), and no statistical evidence
for interactions between the genotypes and these vari-
ables on the risk of cervical carcinoma (Additional
file 1: Table S2).
We calculated the FPRP values for all the observed
significant associations. When the assumption of prior
probability was 0.1, the association with the pri-miR-218
rs11134527 (GG vs. AA/AG) was still noteworthy in
subgroups of premenopausal, SCC, FIGO stage I and
positive pelvic LN (FPRP=0.189, 0.111, 0.163 and 0.153,
respectively) (Additional file 1: Table S3).
To further explore whether the pri-miR-218
rs11134527 variant could alter the local second structure
of the pri-miR-218 mRNA, we performed the RNAfold
online tool that is an online RNA secondary structure
prediction software based on the minimum free energy
(MFE) and found that the MFE changed from −182.5
kcal/mol to −126.0 kcal/mol when the nucleotide at
the pri-miR-218 rs11134527 locus changed from A
to G (Figure 1).
Moreover, using the MDR analysis and including these
two SNPs and three risk factors, we found that age at




Cases Controls P* Crude OR P Adjusted OR P**
(N=1565) (N=1391) (95% CI) (95%CI)
pri-miR-218 rs11134527
AA 588 (37.6) 512 (36.8) 0.085 1.00 1.00
AG 752 (48.1) 638 (45.9) 1.03 (0.88-1.20) 0.748 1.03 (0.87-1.22) 0.705
GG 225 (14.4) 241 (17.3) 0.81 (0.65-1.01) 0.061 0.79 (0.63-0.99) 0.039
AG/GG 977 (62.4) 879 (63.2) 0.668a 0.97 (0.83-1.12) 0.668 0.96 (0.82-1.13) 0.648
Additive model 0.93 (0.84-1.03) 0.148 0.92 (0.82-1.02) 0.111
Recessive model 0.028b 0.80 (0.66-0.98) 0.028 0.77 (0.63-0.95) 0.015
LAMB3 rs2566
CC 667 (42.6) 570 (41.0) 0.431 1.00 1.00
CT 709 (45.3) 663 (47.7) 0.91 (0.78-1.07) 0.252 0.89 (0.76-1.05) 0.165
TT 189 (12.1) 158 (11.4) 1.02 (0.81-1.30) 0.857 0.94 (0.73-1.21) 0.642
CT/TT 898 (57.4) 821 (59.0) 0.366a 0.94 (0.81-1.08) 0.367 0.90 (0.77-1.05) 0.186
Additive model 0.98 (0.88-1.09) 0.707 0.94 (0.84-1.06) 0.325
Recessive model 0.545b 1.07 (0.86-1.34) 0.546 1.00 (0.79-1.27) 1.000
OR, odds ratio; CI, confidence interval.
* χ2 test for genotype distributions between cases and controls;
** Adjusted for age, age at primiparity, menopausal status, BMI in logistic regression models;
a for dominant genetic models;
b for recessive genetic models.
The results were in bold, if P < 0.05.
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est CVC (100%) and the lowest prediction error (43.2%)
among all five discrete factors. Intriguingly, the five-
factor model had a maximum CVC (100%) and a mini-
mum prediction error (38.6%), which showed a better
prediction than one factor (Table 3).
Discussion
In this relatively large hospital-based case–control study of
1,584 cervical cancer cases and 1,394 cancer-free female
controls, we validated two previously reported significant
miRNA-related SNPs involved in the LAMB3-miR-218
pathway for the risk of cervical carcinoma in Chinese popu-
lations [6]. We found that the pri-miR-218 rs11134527 vari-
ant GG genotype was significantly associated with a
decreased risk of cervical carcinoma compared with the
AA and AA/AG genotypes, and our sample size had a stat-
istical power of 94.9% to detect such an association. Further
RNAfold prediction analysis showed a MFE changed from
−182.5 kcal/mol to −126.0 kcal/mol, when the nucleotide at
the pri-miR-218 rs11134527 locus changed from A to G,
indicating that this variant may act as a functional SNP,
which affects the miRNA binding process and contributes
to cervical cancer susceptibility. However, for the other
SNP (i.e., LAMB3 rs2566), our data did not have statistical
evidence to support its association with cervical cancer risk.
Our sample size had 100% statistical power to detect an
OR of 1.57 that was reported by Zhou et al. [6]. Theinconsistency for the LAMB3 rs2566 SNP between Zhou’s
study and ours may be caused by differences in selection of
subjects, different catchments of the hospitals and residen-
tial regions as well as different sample sizes.
Recent studies have demonstrated that miRNAs may
function as tumor suppressors and/or oncogenes in
human cancers [21,22], because elevated or decreased
expression of miRNAs has been found in various tumor
types, which may alter the regulation of mRNA expres-
sion. It is of note that miRNAs regulate gene expression
by the sequence-specific binding to the target mRNA,
and these binding processes may be affected by SNPs
located in the miRNA complementary site [23]. There-
fore, it is important to understand the functional and
evolutionary significance of related genetic variations in
determining expression of miRNAs and mRNAs that
interact with each other as well as with environmental
risk factors in the related biological processes [23,24].
It is well known that genetic variants may modify can-
cer risk associated with environmental factors. Although
there were no two-factor interactions between geno-
types and environmental factors, using the MDR
analysis [18], we further explored high-order mul-
tiple-factor interactions in associations with cervical
cancer risk and found that age at primiparity was
the strongest risk predictor among all the risk fac-
tors considered. Meanwhile, the interaction between
the variant genotypes and other risk factors appeared
Table 2 Stratification analysis for associations between genotypes of the LAMB3-miR-218 pathway and cervical cancer
risk in the recessive genetic model
Variables rs11134527 Adjusted OR*
(95% CI)




AA/AG GG CC/CT TT
Age, years
≤46 (Mean) 747/623 136/131 0.84 (0.64-1.11) 0.215 0.364 774/669 109/85 1.02 (0.74-1.40) 0.919 0.740
>46 (Mean) 593/527 89/110 0.77 (0.56-1.06) 0.111 602/564 80/73 1.00 (0.69-1.45) 0.995
Age at primiparity, years
≤24 (Mean) 797/568 136/131 0.73 (0.56-0.96) 0.022 0.452 822/625 111/74 1.12 (0.82-1.54) 0.482 0.460
>24 (Mean) 468/566 76/106 0.86 (0.62-1.20) 0.386 481/591 63/81 0.91 (0.63-1.32) 0.621
Menopausal status
Premenopausal 962/685 164/155 0.73 (0.57-0.94) 0.013 0.425 986/743 140/97 1.00 (0.75-1.34) 0.981 0.635
Postmenopausal 366/463 61/86 0.90 (0.62-1.32) 0.600 381/488 46/61 1.09 (0.70-1.70) 0.696
BMI, kg/m2
< 25 1026/759 175/157 0.79 (0.62-1.00) 0.054 0.715 1061/810 140/106 1.00 (0.75-1.32) 0.973 0.739
≥ 25 288/390 47/84 0.74 (0.50-1.12) 0.152 295/422 40/52 1.02 (0.64-1.63) 0.939
Histology
CINIII 129/1150 32/241 1.06 (0.68-1.66) 0.789 0.169 137/1233 24/158 1.32 (0.80-2.16) 0.274 0.409
SCC 1068/1150 170/241 0.74 (0.59-0.92) 0.008 1096/1233 142/158 0.95 (0.73-1.22) 0.673
Non-squamous 138/1150 23/241 0.75 (0.46-1.22) 0.240 138/1233 23/158 1.18 (0.71-1.96) 0.526
FIGO stage
I 633/1150 97/241 0.70 (0.53-0.91) 0.008 0.796 645/1233 85/158 0.94 (0.70-1.27) 0.689 0.341
II 464/1150 75/241 0.72 (0.54-0.97) 0.028 478/1233 61/158 0.96 (0.69-1.35) 0.830
III~IV 43/1150 5/241 0.43 (0.15-1.28) 0.129 39/1233 9/158 1.97 (0.83-4.71) 0.126
Tumor size, cm
< 4 801/1150 139/241 0.78 (0.61-0.99) 0.043 0.695 840/1233 100/158 0.88 (0.66-1.16) 0.365 0.100
≥ 4 428/1150 69/241 0.71 (0.53-0.97) 0.031 426/1233 71/158 1.25 (0.91-1.72) 0.176
Pelvic LN
Negative 965/1150 174/241 0.83 (0.66-1.04) 0.098 0.095 1002/1233 137/158 1.00 (0.77-1.29) 0.970 0.819
Positive 309/1150 39/241 0.55 (0.37-0.80) 0.002 308/1233 40/158 0.96 (0.64-1.42) 0.828
LVSI
Negative 750/1150 132/241 0.80 (0.63-1.02) 0.073 0.305 783/1233 99/158 0.93 (0.70-1.24) 0.632 0.379
Positive 390/1150 56/241 0.64 (0.46-0.89) 0.008 387/1233 59/158 1.06 (0.75-1.50) 0.755
Depth of cervical stromal invasion
≤ 1/2 584/1150 99/241 0.75 (0.57-0.98) 0.037 0.898 598/1233 85/158 1.08 (0.81-1.45) 0.602 0.709
> 1/2 670/1150 111/241 0.74 (0.57-0.96) 0.022 690/1233 91/158 0.94 (0.70-1.26) 0.660
ER expression
Negative 647/1150 102/241 0.71 (0.55-0.92) 0.011 0.146 671/1233 78/158 0.85 (0.62-1.15) 0.289 0.365
Positive 50/1150 13/241 1.01 (0.51-1.98) 0.982 54/1233 9/158 1.35 (0.65-2.81) 0.428
PR expression
Negative 677/1150 110/241 0.73 (0.56-0.94) 0.014 0.407 703/1233 84/158 0.87 (0.65-1.18) 0.370 0.836
Positive 20/1150 5/241 0.94 (0.32-2.80) 0.911 22/1233 3/158 1.13 (0.33-3.84) 0.851
OR, odds ratio; CI, confidence interval; BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; CIN, cervical intraepithelial neoplasia;
SCC, squamous cell carcinoma; LN, lymph node; LVSI, lympho-vascular space invasion; ER, estrogen receptor; PR, progesterone receptor.
* Logistic regression models with adjustment for age, age at primiparity, menopausal status and BMI;
** Homogeneity test.
The results were in bold, if P < 0.05.
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Figure 1 The secondary structures of the pri-miR-218 mRNA.
These structures were predicted by inputting two 801-nt long pri-
miR-218 DNA sequences centering the rs11134527 locus into
RNAfold, with either (a) the rs11134527-A or (b) rs11134527-G allele.
The figures and the values of minimum free energy were generated
by RNAfold (http://rna.tbi.univie.ac.at).
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five-factor model being the best model.
MiR-218, is encoded by an intron of the SLIT2 tumor
suppressor gene [25], is known to be associated with the
development and progression of several cancers [21,22].
The decreased level of the miR-218 expression has been
observed in cancers of the breast, ovary, lung and stom-
ach [22,26,27], and its low expression level was also cor-
related with tumor stage, LN metastasis and poor
prognosis in gastric cancer [27]. Recently, Martinez et al.
reported a decreased expression level of miR-218 (> 2
fold) in HPV-16 or 18 positive cervical cancer cell lines
(i.e., SiHa, CaSki and HeLa) as well as in cervical tumorTable 3 MDR analysis for the cervical cancer risk prediction w
Number of risk
factors
Best interaction models by MDR analysis
1 age at primiparity
2 age at primiparity, BMI
3 age at primiparity, menopausal status, BMI
4 age at primiparity, menopausal status, BMI, rs2566
5 age at primiparity, menopausal status, BMI,
rs11134527, rs2566
MDR, multifactor dimensionality reduction.
The multi-locus model with maximum cross-validation consistency and minimum ptissues [12]. They also demonstrated miR-218 as a spe-
cific cellular target of high-risk HPV types [12], suggest-
ing that the down-regulation of miR-218 is likely linked
to the process of HPV-associated tumorgenesis. Based
on the Microcosm Targets tool software (http://www.ebi.
ac.uk/enright-srv/microcosm/), the mature miR-218 was
found to have an effect on the mRNA expression regula-
tion through more than 900 target genes, including
LAMB3 [12], RICTOR [28], ROBO1 [27] and BIRC5
[29], that may play important roles in cervical carcino-
genesis. These genes were reported to participate in a
number of cancer signaling pathways, such as the Wnt/
β-catenin, ERK/MAPK and Notch pathways [30].
Laminin-5 has been found as a sensitive marker of early
invasion of cervical lesions [31]. LAMB3 that expressed
in many epithelial tissues could induce carcinogenesis by
increasing carcinoma cell migration and disturbing tumor
microenvironment [13]. Moreover, LAMB3 increased ex-
pression levels of the HPV16 E6 oncoprotein in cervical
cancer cells and this process might be mediated by miR-
218 [12], which indicates a possible mechanism of the
LAMB3-miR-218 pathway involved in the development of
cervical carcinoma.
It is known that the mRNA secondary structure is crit-
ical for mRNA-miRNA interactions and gene functions
[32]. To investigate whether the pri-miR-218 rs11134527
SNP could alter the local second structure of the pri-
miR-218 mRNA, we performed the RNAfold prediction
analysis and found an obviously changed mRNA struc-
ture from rs11134527 allele A to G. These findings
further suggest that germline genetic variations of pri-
miR-218, such as rs11134527, may lead to an alteration
of miR-218 expression and affect the miRNA binding
process and thus are associated with cervical cancer
susceptibility.
Several limitations of our study need to be addressed.
Firstly, this hospital-based case–control study may have
selection bias and information bias, which may be mini-
mized by frequency-matching cases and controls as well
as the adjustment for potential confounding factors in
the final analyses. Secondly, only two miR-218-related












rediction error rate is indicated in bold.
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were investigated in this study. Cancer is a complex and
multifactorial disease, and any single SNP may not be
sufficient for the prediction of the overall risk [33]. Fu-
ture studies should include more genes and more SNPs,
especially functional ones, associated with cervical can-
cer risk. Finally, we did not have enough information on
other risk factors, especially HPV infection. This was be-
cause the hospital did not perform HPV and related sub-
type detection for the diagnosis of all cervical cancer
cases, let alone for the female controls. A recent meta-
analysis found that high-risk HPV16, 18 and 45 types
accounted for a greater or equal proportion of HPV
infections in cervical cancer, but not other high-risk
HPV types, such as HPV33, 51 and 58 [34]. Therefore,
HPV types could be confounders in estimating the risk
associated with genetic factors.
Conclusions
In summary, in the current case–control study of 1,584
cases and 1,394 controls, we found that the pri-miR-218
rs11134527 SNP was associated with the risk of cervical
carcinoma in Eastern Chinese women. Our findings sug-
gest some possible interactions between genetic varia-
tions involved in the LAMB3-miR-218 pathway and
other risk factors for cervical carcinoma. However, well-
designed prospective studies with larger sample sizes are
required to validate our findings.
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